Pfizer-BioNTech Begin Late-stage Study of Lead Covid-19 Vaccine Candidate

If the study is successful, the companies could submit the vaccine for regulatory approval as early as October, putting them on track to supply up to 100 million doses by the end of 2020 and 1.3 billion by the end of 2021.

https://ift.tt/39vPDNX
https://ift.tt/30V8HRE